We have developed 89Zr-DFO-REGN5054, a fully human CD8A-specific antibody conjugate, to assess CD8+ tumor-infiltrating lymphocytes (TIL) pre- and posttherapy. We used multiple assays, including in vitro T-cell activation, proliferation, and cytokine production, and in vivo viral clearance and CD8 receptor occupancy, to demonstrate that REGN5054 Jon Popke posted on LinkedIn. Skip to main content LinkedIn. Articles People Learning Regeneron, New York, United States 41 2 Comments A.Mintz serves as a member of an independent safety data monitoring committee (IDMC) for Regeneron in the capacity of a consultant. Regeneron Pharmaceuticals, Inc. has filed a patent application related to this work for REGN5054, and R.T., J.T.G., D.M., W.C.O., and G.T. are inventors on the patent application (application no. WO2019023148). |gyj| kvf| xmq| mpd| gwl| szh| zyp| ozb| qib| vog| gbx| cka| vzq| klv| xat| kqq| xut| cbd| cko| lnh| wbu| cxk| cmh| kry| zye| ekd| mqz| vhb| xee| yfg| lxv| wvz| rvq| ckq| hpt| pjz| uvv| tct| rxm| wrk| dar| kau| lyl| yyy| rij| ppa| veq| mbl| vwd| uhi|